Solute carriers as potential oncodrivers or suppressors: their key functions in malignant tumor formation.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
29
11
2020
revised:
15
02
2021
accepted:
07
03
2021
pubmed:
20
3
2021
medline:
18
1
2022
entrez:
19
3
2021
Statut:
ppublish
Résumé
Solute carrier (SLC) transporters are primarily known for their function in the transportation of various exogenous/endogenous substances via influx/efflux mechanisms. In addition to their diverse role in several tumor-modulating functions, such as proliferation, migration, angiogenesis, epithelial-mesenchymal transition (EMT), epigenetic modification, chemoresistance, immunoregulation, and oncometabolism, influx/efflux-independent contributions of SLCs in the activation of various signaling network cascades that might drive metastatic tumor formation have also been uncovered. Disappointingly, even after two decades and the discovery of >450 SLCs, many of their members remain orphans in terms of cancer pathogenesis. In this review, we summarize the current understanding of the tumor-modulating functions, mechanisms, and complexity of SLCs, as well as their potential as targets for cancer therapy.
Identifiants
pubmed: 33737072
pii: S1359-6446(21)00138-0
doi: 10.1016/j.drudis.2021.03.004
pii:
doi:
Substances chimiques
Membrane Transport Proteins
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1689-1701Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.